Safety Alert for Trade Name: Triacel FR10ml Reagent. Technical Name: Hemocyte Reagent Family for Immunohematology. ANVISA registration number: 10154450145. Risk class: III. Model affected: Triacel 2 x 10ml. Serial numbers affected: 71LK20EB

According to Agência Nacional de Vigilância Sanitária (ANVISA), this safety alert involved a device in Brazil that was produced by Fresenius Hemocare Brasil Ltda; Fresenius Hemocare Brasil Ltda.

What is this?

Alerts provide important information and recommendations about products. Even though an alert has been issued, it does not necessarily mean a product is considered to be unsafe. Safety Alerts, addressed to health workers and users, may include recalls. They can be written by manufacturers, but also by health officials.

Learn more about the data here
  • Type of Event
    Safety alert
  • Event ID
    2423
  • Date
    2017-12-01
  • Event Country
  • Event Source
    ANVISA
  • Event Source URL
  • Notes / Alerts
    Brazilian data is current through June 2018. All of the data comes from Anvisa, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Brazil.
  • Extra notes in the data
    This deviation is related only to the diagram, which has already been duly corrected, therefore, the product can be used normally. UPDATE (03/19/2018): The company completed the field action on 01/20/2018. If you wish to notify technical complaints and adverse events use the following channels: Notivisa: Notices of adverse events (AE) and technical complaints (QT) for products subject to Sanitary Surveillance should be made through the NOTIVISA System. To access the System, you must register and select the Health Professional option, if you are a liberal professional or the Institution / Entity option, if you are a professional of an institution / entity. Technovigilance System: Patient or citizen can notify through the Technovigilance System / SISTEC access through the link Additional information: - Date of identification of the problem by the company: 10/20/2017 - Date of notification notice to Anvisa: 12/01/2017 The company that owns the affected product is responsible for contacting its customers in a timely manner. to ensure the effectiveness of the Field Action in progress. It stands out the joint responsibility of the distribution chain and use of health products in maintaining its quality, safety and efficacy, as well as the effectiveness of the Field Action, expressed by RDC 23/2012: "(...) Art 2 ° A holder of registration of health product is the holder of the registration / registration of health product with Anvisa. Single paragraph. The registration holder, as well as other agents involved from the production to the use of the product, or discarding it when applicable, are jointly and severally responsible for maintaining the quality, safety and efficacy of the health products to the final consumer. Art. 12 Distributors of health products shall forward to the registration holder, in a timely manner, the distribution map and other information requested for the notification and execution of field actions. (...) "
  • Reason
    On october 20, at the end of the afternoon, we received a complaint, where the client mentioned that during his qc tests, one of the antigens showed a positive result, presence of p1 antigen, instead of negative, as indicated in the product diagram . according to the customer, cell ii of triacel reagent from lot 71lk20eb indicated in the diagram as negative for p1 antigen. however, in the qc tests, this cell showed positive results. therefore, we identified that the diagram distributed to the clients, the p1 antigen of cell ii was marked negative (o). lot 71lk20eb would begin to be used the next day, as the lot in use would expire on october 20.
  • Action
    Field Action Code 03-2017 triggered under the responsibility of the company Fresenius Hemocare Brasil Ltda. Inform that there was an error in the red cell diagram.

Manufacturer